Overton Among Final FDA Commissioner Candidates; Lilly
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Heidi Overton is among the final candidates the Trump administration is considering to lead the FDA, per Bloomberg, though no decision has been made and it remains unclear whether HHS Secretary Robert F. Kennedy Jr. supports her.
- Overton is a deputy assistant to the president for domestic policy at the White House, previously worked at the America First Policy Institute, holds an MD and a doctorate in clinical investigation from Johns Hopkins, and was a White House fellow during the first Trump administration.
- Eli Lilly expects to launch its weight loss pill in Europe and the U.K. in the second half of 2026 or early 2027, targeting the out-of-pocket telehealth market as it has done in the U.S.
- Lilly still plans to pursue public reimbursement from European governments where possible, with pricing aligned to its interpretation of the Trump administration's 'most-favored nation' framework, which links European prices to U.S. net prices adjusted for countries' income levels.
Why it matters: FDA leadership under a White House aide without confirmed backing from the HHS secretary signals continued uncertainty over the agency's direction during a period of ongoing regulatory change, while Lilly's 2026 European launch under a 'most-favored nation' framework would anchor EU and U.K. drug prices to U.S. net prices — setting a precedent other pharma companies may face in cross-border reimbursement negotiations.
Ask SkimNews
